Insider traders often operate on undisclosed information, giving them an unfair edge in forecasting stock market movements.
In this case, U.S. Representative Earl Blumenauer appeared to know about a favorable judicial decision regarding Koninklijke Philips (NYSE: PHG) and its U.S. respiratory lawsuit.
The stock has surged by 28.57% following Blumenauer’s purchase, with a 26% gain over the last three trading sessions, conveniently aligning with the verdict’s delivery as Blumenauer purchased the stock on February 12 and disclosed the purchase on March 2.
Blumenauer’s position on the health subcommittee makes this trade even more suspicious.
Philips US settlement and quarterly results caused the surge
Philips, the medical device manufacturer, reached a nearly $1.1 billion settlement for personal injury claims related to certain CPAP, ventilator, and BiPAP machines following a major recall in 2021.
Additionally, a $25 million settlement for medical monitoring was agreed upon. Despite not admitting fault or liability, Philips aimed to compensate individuals in the US who sued, alleging harm from the faulty devices.
In addition to an unlimited settlement offering over $600 million in economic compensation to affected device owners, the latest agreement has been reached.
The settlement announcement coincided with Philips’ first-quarter financial results, which were mainly positive and aligned with expectations, leading to a significant rise in PHG stock.
PHG stock price chart
With the positive developments during recent trading sessions, PHG stock is trading at a price of $26.55 after experiencing a slight setback of 0.60% in the last trading session. This is negated by a significant gain of 26.61% in the previous five trading sessions.
On a YTD chart, PHG shares show a healthy progress of 14.34%.
With the legal roadblocks cleared, Philips seems set to reclaim its lost share of the US healthcare industry, potentially yielding Blumenauer even more profits.
Buy stocks now with eToro – trusted and advanced investment platform
Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.
